EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Switch to English

10367	Sociétés
215873	Mots-clés
145598	Articles
114306	Communiqués

Accueil
Sociétés
EnVVeno Medical Corporation

COMMUNIQUÉ DE PRESSE

publié le 16/04/2024 à 15:00, il y a 2 années

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
COMMUNIQUÉ DE PRESSE

publié le 09/04/2024 à 14:45, il y a 2 années

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 1 mois

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 1 mois

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
COMMUNIQUÉ DE PRESSE

publié le 15/03/2024 à 14:00, il y a 2 années 1 mois

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 2 mois

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 2 mois

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
COMMUNIQUÉ DE PRESSE

publié le 06/03/2024 à 14:40, il y a 2 années 2 mois

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Les Echos

Publié le 07/05/2026 à 15:00, il y a 1 heure 36 minutes

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Publié le 07/05/2026 à 07:43, il y a 8 heures 52 minutes

ENGIE - Q1 2026 financial information
Publié le 07/05/2026 à 07:43, il y a 8 heures 52 minutes

ENGIE - Information Financière 1er trimestre 2026
Publié le 06/05/2026 à 18:00, il y a 22 heures 35 minutes

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Publié le 06/05/2026 à 18:00, il y a 22 heures 35 minutes

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 07/05/2026 à 15:15, il y a 1 heure 21 minutes

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Publié le 07/05/2026 à 14:35, il y a 2 heures 1 minute

Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Publié le 07/05/2026 à 14:30, il y a 2 heures 6 minutes

Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Publié le 07/05/2026 à 14:30, il y a 2 heures 6 minutes

Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook
Publié le 07/05/2026 à 14:00, il y a 2 heures 36 minutes

Adcore to Publish First Quarter 2026 Results on May 14, 2026

Voir tout ACCESSWIRE

EQS Group

Publié le 07/05/2026 à 16:25, il y a 10 minutes

VARON Reinforces Commitment to Seasonal Respiratory Wellness During Allergy Season Across Europe
Publié le 07/05/2026 à 16:25, il y a 10 minutes

Medit Establishes Global Orthodontic Business Division, Anchored by Strategic Acquisition of Progressive Orthodontics
Publié le 07/05/2026 à 16:15, il y a 21 minutes

157th Annual General Meeting at wienerberger: All Resolutions Adopted
Publié le 07/05/2026 à 15:55, il y a 40 minutes

MENARINI GROUP: THOMAS CUENI APPOINTED NEW MEMBER OF THE BOARD
Publié le 07/05/2026 à 15:28, il y a 1 heure 8 minutes

JOST’s Annual General Meeting approves dividend of EUR 1.50 per share and elects new Supervisory Board member